Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date23 Jul 1976 |
Analysis of clinical situation and treatment patterns in CIDP patients based on claims data in Japan - Analysis of clinical situation and treatment patterns in CIDP patients based on claims data in Japan
The clinical impact of immunoglobulin replacement therapy on severe bacterial infection for patients with hypogammaglobulinemia secondary to hematologic malignancies: A Japanese claims database study - A database study on immunoglobulin replacement therapy in patients with secondary hypogammaglobulinemia
An open-label, single-arm, non-randomized phase 3 study to evaluate clinical efficacy, safety, and pharmacokinetics of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects
100 Clinical Results associated with CSL Behring KK
0 Patents (Medical) associated with CSL Behring KK
100 Deals associated with CSL Behring KK
100 Translational Medicine associated with CSL Behring KK